Efficacy of combination treatment with arsenic trioxide and all-trans retinoic acid on acute promyelocytic leukemia therapy

在这项研究中，我们进行了基础实验，以确定全反式维甲酸(ATRA)和三氧化二砷(ATO)联合治疗急性早幼粒细胞白血病(APL)是否比单一药物治疗更有益。为了确定ATRA诱导的分化是否被ATO所增强，我们比较了ATRA、ATO以及ATRA与ATO合用对人白血病HL60细胞表面CD11b表达的影响。结果表明，ATO与ATRA合用对HL60细胞有进一步的分化作用，提示ATO与ATRA合用对HL60细胞的分化促进作用比单独用ATRA更有效。

In this study, we performed basic experiments to determine whether the treatment with all-trans retinoic acid(ATRA) plus arsenic trioxide(ATO) in combination is beneficial in Acute Promyelocytic Leukemia(APL) therapy than that with a single agent. In order to determine the ATRA-induced differentiation is augmented by the addition of ATO, we compared the surface expression of CD 11 b in human leukemia HL60 cells incubated with ATRA, ATO, or ATRA plus ATO. The result indicates that HL60 cells treated with ATO plus ATRA show further differentiation than those treated with ATRA alone, suggesting that cotreatment of ATO plus ATRA is more effective than the treatment with a single agent in enhancing the differentiation of HL60 cells.